DDInter1263 DDInter1435
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Naltrexone {u} may lead to a major life threatening interaction when taken with {v} Oxycodone
Naltrexone {u} (Compound) resembles {v} (Compound) Hydrocodone
Naltrexone {u} (Compound) resembles {v} (Compound) Butorphanol
Naltrexone {u} (Compound) treats {v} (Disease) alcohol dependence
Naltrexone {u} (Compound) binds {v} (Gene) OPRD1
Naltrexone {u} (Compound) upregulates {v} (Gene) TSC22D3
Naltrexone {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Antagonists
Naltrexone {u} (Compound) downregulates {v} (Gene) IER3
Naltrexone {u} (Compound) causes {v} (Side Effect) Dyspnoea
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorzoxazone
Naltrexone may lead to a major life threatening interaction when taken with Oxycodone
Naltrexone (Compound) resembles Hydrocodone (Compound)
Naltrexone (Compound) resembles Butorphanol (Compound)
Naltrexone (Compound) treats alcohol dependence (Disease)
Naltrexone (Compound) binds OPRD1 (Gene)
Naltrexone (Compound) upregulates TSC22D3 (Gene)
Naltrexone (Compound) is included by Opioid Antagonists (Pharmacologic Class)
Naltrexone (Compound) downregulates IER3 (Gene)
Naltrexone (Compound) causes Dyspnoea (Side Effect)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone